Canaccord Genuity Group Reaffirms Buy Rating for ASP Isotopes (NASDAQ:ASPI)

Canaccord Genuity Group restated their buy rating on shares of ASP Isotopes (NASDAQ:ASPI) in a research note issued to investors on Friday morning, Benzinga reports. They currently have a $4.50 target price on the stock.

A number of other analysts have also commented on the company. Canaccord Genuity Group began coverage on ASP Isotopes in a report on Friday, October 4th. They issued a “buy” rating and a $4.50 price target on the stock. HC Wainwright cut their price target on ASP Isotopes from $5.50 to $4.50 and set a “buy” rating on the stock in a report on Wednesday, August 7th.

ASP Isotopes Stock Performance

ASPI stock opened at $4.28 on Friday. The business’s 50-day moving average price is $2.66 and its two-hundred day moving average price is $3.24. The company has a current ratio of 4.00, a quick ratio of 4.00 and a debt-to-equity ratio of 2.06. The firm has a market cap of $221.55 million, a PE ratio of -8.08 and a beta of 5.11. ASP Isotopes has a 1-year low of $0.98 and a 1-year high of $5.67.

ASP Isotopes (NASDAQ:ASPI) last posted its earnings results on Monday, August 19th. The company reported ($0.24) earnings per share for the quarter. The business had revenue of $1.02 million during the quarter. As a group, research analysts forecast that ASP Isotopes will post -0.24 earnings per share for the current year.

Institutional Trading of ASP Isotopes

A number of institutional investors have recently modified their holdings of the company. Marshall Wace LLP raised its holdings in ASP Isotopes by 389.6% during the second quarter. Marshall Wace LLP now owns 545,072 shares of the company’s stock worth $1,668,000 after acquiring an additional 433,734 shares in the last quarter. Renaissance Technologies LLC raised its holdings in ASP Isotopes by 5.7% during the second quarter. Renaissance Technologies LLC now owns 171,800 shares of the company’s stock worth $526,000 after acquiring an additional 9,200 shares in the last quarter. Rathbones Group PLC raised its holdings in ASP Isotopes by 27.5% during the second quarter. Rathbones Group PLC now owns 195,915 shares of the company’s stock worth $600,000 after acquiring an additional 42,243 shares in the last quarter. Rhumbline Advisers bought a new stake in ASP Isotopes during the second quarter worth about $116,000. Finally, Fielder Capital Group LLC bought a new stake in ASP Isotopes during the second quarter worth about $55,000. 16.80% of the stock is currently owned by institutional investors.

ASP Isotopes Company Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.